Home > Journals > Minerva Biotechnology and Biomolecular Research > Past Issues > Minerva Biotecnologica 2009 December;21(4) > Minerva Biotecnologica 2009 December;21(4):217-30

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions
Share

 

BIOMATERIALS - PART II   

Minerva Biotecnologica 2009 December;21(4):217-30

Copyright © 2010 EDIZIONI MINERVA MEDICA

language: English

Bioabsorbable polymeric drug-eluting endovascular stents. A clinical review

Soares J. S. 1, 2

1 MOX – Modeling and Scientific Computing Department of Mathematics “F. Brioschi”, Polytechnic of Milan, Milan, Italy 2 CEMAT – Center for Mathematics and its Applications, Department of Mathematics, Instituto Superior Técnico, Lisboa, Portugal


PDF


Percutaneous transluminal balloon angioplasty followed by drug-eluting stent implantation has been of great benefit in coronary applications, whereas in peripheral applications, success rates remain low. Analysis of healing patterns in successful deployments shows that six months after implantation the artery has reorganized itself to accommodate the increase in caliber and there is no purpose for the stent to remain, potentially provoking inflammation and foreign body reaction. Late stent thrombosis due to incomplete re-endothelialization is currently the biggest concern associated with permanent drug eluting stents and strut fractures are occurring at an increasing rate. As mechanical scaffolding of the artery is not necessary once the artery has healed, a fully biodegradable polymeric stent that naturally avoids long term problems inherent to permanent stents is of great benefit. Biodegradable polymers have a widespread usage in the biomedical field, such as in sutures, scaffolds and implants. There have been major established efforts to develop biodegradable stent technology, yet so far none have been approved for commercial use. Bioabsorbable stents are on the cusp of a new era in minimally invasive intervention, which is characterized by the paradigm of dynamic implants. Stents that actively change over time – optimizing success, working in concert with the time dependent body’s reaction, and enhancing the healing process – is an ambitious goal that requires extensive cooperation between clinicians, industry, and academia.

top of page